We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Alere Updates on 10K Filing, Reports Preliminary Q1 Figures
Read MoreHide Full Article
Alere Inc. recently provided some information about its pending 10K for the year that ended on Dec 31, 2015. Over the last four months, the company has been conducting a review of its operations in Africa and China for the years 2013, 2014 and 2015.
The thorough review process has identified certain misstatements related to revenue recognition and other financial aspects for 2013 and 2014 and the first three quarters of 2015. Although these misstatements are not material to 2013 and 2014 financials, they are expected to affect 2015 figures.
Hence, Alere expects to revise its previously issued annual financial statements for 2013 and 2014 and the interim financial statements of each three quarters of 2015 in the upcoming 10K. However, Alere did not provide any time line and said that it expects to file the 10K with the SEC “as soon as practicable.”
Revenue Estimates Lowered for FY15
Meanwhile, Alere revised down its 2015 revenue guidance. The company now expects to report revenues of almost $2.47 billion, down from $2.48 billion to $2.5 billion guided earlier. Net income from continuing operations is now expected to be in the band of $10-$25 million, while adjusted EBITDA is estimated to be in the range of $505 million to $520 million.
As of Dec 31, 2015, cash and cash equivalents are expected to be $502 million, while total debt is estimated to be $3.07 billion.
Preliminary Q1 Figures
Alere also provided few details about the first quarter 2016 results. The company expects to report revenues in the range of $573-$593 million. Net income from continuing operations is now expected to be in the band of ($8)-$2 million, while adjusted EBITDA is estimated to be in the range of $106 million to $116 million.
As of Dec 31, 2015, cash and cash equivalents are expected to be $492 million, while total debt is estimated to be $3.02 billion.
No Immediate Relief for Alere
Alere’s announcement related to the 10K and the preliminary Q1 figures will certainly calm down bond holders. The figures will also be eagerly scrutinised by Abbott Laboratories (ABT - Free Report) , Alere’s current suitor.
In early February, Abbott offered $5.8 billion to acquire Alere. However, the company tried to break away from the deal following the revelation of the U.S. Department of Justice (DOJ)’s investigation into Alere’s overseas businesses. Reportedly, Abbott also offered a break-up fee, which however did not interest Alere.
The deal continues to face issues like Alere’s recent voluntary recall of the INRatio and INRatio 2 PT/INR Monitoring Systems. According to Bloomberg, the recall is expected to cost Alere between $70 million and $90 million in 2016. Abbott has already expressed its disappointment and is currently reviewing the impact of the recall on Alere’s financials.
Zacks Rank & Key Picks
Alere has a Zacks Rank #3 (Hold).
Better-ranked stocks are Boston Scientific (BSX - Free Report) and NuVasive . Both the stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Alere Updates on 10K Filing, Reports Preliminary Q1 Figures
Alere Inc. recently provided some information about its pending 10K for the year that ended on Dec 31, 2015. Over the last four months, the company has been conducting a review of its operations in Africa and China for the years 2013, 2014 and 2015.
The thorough review process has identified certain misstatements related to revenue recognition and other financial aspects for 2013 and 2014 and the first three quarters of 2015. Although these misstatements are not material to 2013 and 2014 financials, they are expected to affect 2015 figures.
Hence, Alere expects to revise its previously issued annual financial statements for 2013 and 2014 and the interim financial statements of each three quarters of 2015 in the upcoming 10K. However, Alere did not provide any time line and said that it expects to file the 10K with the SEC “as soon as practicable.”
Revenue Estimates Lowered for FY15
Meanwhile, Alere revised down its 2015 revenue guidance. The company now expects to report revenues of almost $2.47 billion, down from $2.48 billion to $2.5 billion guided earlier. Net income from continuing operations is now expected to be in the band of $10-$25 million, while adjusted EBITDA is estimated to be in the range of $505 million to $520 million.
ALERE INC Price, Consensus and EPS Surprise
ALERE INC Price, Consensus and EPS Surprise | ALERE INC Quote
As of Dec 31, 2015, cash and cash equivalents are expected to be $502 million, while total debt is estimated to be $3.07 billion.
Preliminary Q1 Figures
Alere also provided few details about the first quarter 2016 results. The company expects to report revenues in the range of $573-$593 million. Net income from continuing operations is now expected to be in the band of ($8)-$2 million, while adjusted EBITDA is estimated to be in the range of $106 million to $116 million.
As of Dec 31, 2015, cash and cash equivalents are expected to be $492 million, while total debt is estimated to be $3.02 billion.
No Immediate Relief for Alere
Alere’s announcement related to the 10K and the preliminary Q1 figures will certainly calm down bond holders. The figures will also be eagerly scrutinised by Abbott Laboratories (ABT - Free Report) , Alere’s current suitor.
In early February, Abbott offered $5.8 billion to acquire Alere. However, the company tried to break away from the deal following the revelation of the U.S. Department of Justice (DOJ)’s investigation into Alere’s overseas businesses. Reportedly, Abbott also offered a break-up fee, which however did not interest Alere.
The deal continues to face issues like Alere’s recent voluntary recall of the INRatio and INRatio 2 PT/INR Monitoring Systems. According to Bloomberg, the recall is expected to cost Alere between $70 million and $90 million in 2016. Abbott has already expressed its disappointment and is currently reviewing the impact of the recall on Alere’s financials.
Zacks Rank & Key Picks
Alere has a Zacks Rank #3 (Hold).
Better-ranked stocks are Boston Scientific (BSX - Free Report) and NuVasive . Both the stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>